NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,624−0.16%VIX25.64−9.01%latest tape · as of 02:03 UTC
The Screen · Industrials · Building Products & Equipment
NXQuanex Building Products Corporation
NX · the NYSE · USD · Market cap $923M · 7,071 employees
Quanex Building Products Corporation, together with its subsidiaries, manufactures and distributes components for original equipment manufacturers (OEM) in the building products industry in the United States, Europe, Can…
FAIL · Does not pass the screen
20.70 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 02:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price20.70 USD at the 6 Nov 2026 close
Our value readFair vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-11-03
Ethical does not pass the values gate
Price20.70 USD
Fair value20.02
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-11-01Read Accumulation20.67+0.1% to today ✓Markdown gives way to Accumulation
2026-10-11Read Markdown20.10+3.0% to today Markup gives way to Markdown first Markdown read since September
2026-10-02Read Markup20.10+3.0% to today ✓Markdown gives way to Markup after an 11% rise in 3 weeks
2026-09-08Read Markdown18.17+13.9% to today Markup gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Quanex Building Products Corporation holds its Markup at $20.70. The statistical read favours the sellers, held for 19 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 19 days
Price at the screen
$20.70
Valuation
N/A trailing · 9.56 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.92
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
43.38%
Below 33%
Interest-bearing debt is 43.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
14.15%
Below 49%
Money owed to the company is 14.2% of assets, under the 49% limit.
Pass
Revenue purity
0.11%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Quanex Building Products's business is in a permissible area, but its interest-bearing debt is about 43% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NX's ethical verdict changes
Today NX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades above our $20.02 fair value estimate, 2.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 3.4% above the base estimate.
Third-party analyst targets. The average target sits +30% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NX trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-10-25Markdown$18.21+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-10-18Markdown$18.21-9.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-10-11Markdown · changed$20.10+0.0%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-10-02Markup · changed$20.10+10.6%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-09-08Markdown · changed$18.17+0.0%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-08-07Markup · changed$18.17+6.8%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-07-18Distribution$17.02+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $28.
2026-07-03Distribution$17.02+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$17.02Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.